Appeals Court Rejects Novo Nordisk Challenge to Medicare Drug Pricing Plan

Similar rulings have come against other drugmakers that filed suits over the program, including Novartis and Bristol Myers Squibb.

Flags with the logo of Novo Nordisk, the maker of Ozempic and Wegovy, in a file image. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images

A federal appeals court on Oct. 6 rejected a challenge from Novo Nordisk to the Medicare drug pricing plan included in the Biden-era Inflation Reduction Act (IRA).

The plan does not violate the Constitution’s First Amendment, a unanimous panel of judges from the U.S. Court of Appeals for the Third Circuit said in a 22-page decision.